Should I buy or sell Brainstorm Cell Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BCLI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCLI, but not buy additional shares or sell existing shares. View BCLI analyst ratings or view top-rated stocks .

How have BCLI shares performed in 2024?

Brainstorm Cell Therapeutics' stock was trading at $0.2730 at the beginning of the year. Since then, BCLI stock has increased by 90.1% and is now trading at $0.5190. View the best growth stocks for 2024 here .

Are investors shorting Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,340,000 shares, an increase of 57.6% from the March 15th total of 850,300 shares. Based on an average daily volume of 1,040,000 shares, the days-to-cover ratio is presently 1.3 days. View Brainstorm Cell Therapeutics' Short Interest .

When is Brainstorm Cell Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our BCLI earnings forecast .

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) announced its quarterly earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.14) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.14). During the same period in the prior year, the company earned ($0.19) earnings per share.

What other stocks do shareholders of Brainstorm Cell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO) , Gene Biotherapeutics (CRXM) , Anavex Life Sciences (AVXL) , Sangamo Therapeutics (SGMO) , Mellanox Technologies (MLNX) , Caladrius Biosciences (CLBS) , Abeona Therapeutics (ABEO) and Adaptimmune Therapeutics (ADAP) .

Who are Brainstorm Cell Therapeutics' major shareholders?

Brainstorm Cell Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Kingswood Wealth Advisors LLC (0.12%). View institutional ownership trends .

How do I buy shares of Brainstorm Cell Therapeutics?

Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BCLI

Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free BCLI Stock Alerts

$0.53

-0.02 (-3.23%)

(As of 01:34 PM ET)

Compare

Today's Range: $0.45
▼
$0.57
50-Day Range: $0.31
▼
$0.74
52-Week Range: $0.13
▼
$3.37

Volume: 503,628 shs
Average Volume: 1.02 million shs
Market Capitalization: $36.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Brainstorm Cell Therapeutics alerts:

Brainstorm Cell Therapeutics MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.96% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.66
Upright™ Environmental Score
News Sentiment: 0.55
Based on 10 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.74 out of 5 stars

Medical Sector

859th out of 930 stocks

Biological Products, Except Diagnostic Industry

149th out of 155 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Brainstorm Cell Therapeutics.

3.0

Short Interest

Percentage of Shares Shorted
1.96% of the outstanding shares of Brainstorm Cell Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Brainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Brainstorm Cell Therapeutics has recently increased by 57.59%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Brainstorm Cell Therapeutics does not currently pay a dividend.
Dividend Growth
Brainstorm Cell Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Brainstorm Cell Therapeutics has received a 76.26% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for the nervous system", "Preclinical research services for physical health", and "Preclinical research services for mental health" products. See details.
Environmental Sustainability
The Environmental Impact score for Brainstorm Cell Therapeutics is -0.66.

3.1

News and Social Media Coverage

News Sentiment
Brainstorm Cell Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Brainstorm Cell Therapeutics this week, compared to 2 articles on an average week.
Search Interest
17 people have searched for BCLI on MarketBeat in the last 30 days. This is an increase of 467% compared to the previous 30 days.
MarketBeat Follows
8 people have added Brainstorm Cell Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Brainstorm Cell Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.45% of the stock of Brainstorm Cell Therapeutics is held by insiders.
Percentage Held by Institutions
Only 14.33% of the stock of Brainstorm Cell Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Brainstorm Cell Therapeutics are expected to remain at ($0.47) per share in the coming year.
Price to Earnings Ratio vs. the Market
The P/E ratio of Brainstorm Cell Therapeutics is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Brainstorm Cell Therapeutics is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

About Brainstorm Cell Therapeutics Stock (NASDAQ:BCLI)

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

BCLI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BCLI Stock News Headlines

April 15, 2024 | americanbankingnews.com

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Expected to Earn Q1 2024 Earnings of ($0.07) Per Share

April 11, 2024 | finanznachrichten.de

BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule

April 16, 2024 | Crypto Swap Profits (Ad)

Claim Your Complimentary Bitcoin Reward

Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

April 11, 2024 | finance.yahoo.com

BCLI: Receives SPA Agreement from FDA on Design of Phase 3b Trial of NurOwn™…

April 11, 2024 | prnewswire.com

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule

April 10, 2024 | finance.yahoo.com

BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS

April 10, 2024 | prnewswire.com

BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS

April 9, 2024 | finance.yahoo.com

BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

April 16, 2024 | Crypto Swap Profits (Ad)

Claim Your Complimentary Bitcoin Reward

April 9, 2024 | prnewswire.com

BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

April 9, 2024 | americanbankingnews.com

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Passes Above Two Hundred Day Moving Average of $0.31

April 8, 2024 | prnewswire.com

BrainStorm Cell Therapeutics to Provide Update on NurOwn Program

April 1, 2024 | benzinga.com

Brainstorm Cell: Q4 Earnings Insights

April 1, 2024 | prnewswire.com

BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update

March 25, 2024 | msn.com

Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session

March 6, 2024 | finance.yahoo.com

BCLI: Unveils Plans for Phase 3b Trial of NurOwn® in ALS…

February 29, 2024 | investing.com

BrainStorm details Phase 3b trial for ALS treatment NurOwn

February 27, 2024 | finance.yahoo.com

BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference

February 27, 2024 | prnewswire.com

BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference

February 25, 2024 | finance.yahoo.com

BCLI Mar 2024 1.500 call

February 23, 2024 | marketwatch.com

BrainStorm Cell Therapeutics Shares Rise 7.2% on NurOwn Study Request to FDA

February 23, 2024 | msn.com

BrainStorm submits SPA request to FDA for Phase 3 study design

February 23, 2024 | prnewswire.com

BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS

February 16, 2024 | wsj.com

Brainstorm Cell Therapeutics Inc.

February 13, 2024 | uk.investing.com

Brainstorm Cell Therapeutics Inc (BCLI)

February 13, 2024 | finance.yahoo.com

BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum

February 1, 2024 | finance.yahoo.com

Brainstorm Cell Therapeutics Inc. (BCLI)

See More Headlines

Receive BCLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 4/16/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:BCLI
CUSIP: N/A
CIK: 1137883
Web: www.brainstorm-cell.com
Phone: (201) 488-0460
Fax: N/A
Employees: 42
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.41)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,190,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -376.40%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.24
Quick Ratio: 0.24

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.08) per share
Price / Book: -6.86

Miscellaneous

Outstanding Shares: 68,340,000
Free Float: 64,617,000
Market Cap: $37.50 million
Optionable: Optionable
Beta: 0.27

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Chaim Lebovits (Age 53)
President & CEO
Comp: $990.42k
Dr. Stacy R. Lindborg Ph.D. (Age 54)
Co-Chief Executive Officer
Comp: $708.39k
Dr. Irit Arbel DSc (Age 64)
Ph.D., Co-Founder & Independent Vice Chair of the Board
Mr. Uri Yablonka (Age 47)
Executive VP, Chief Business Officer, Secretary & Director
Ms. Alla Patlis CPA (Age 37)
M.B.A., Controller & Interim CFO
Comp: $80k
Dr. Daniel Offen Ph.D.
Chief Scientific Advisor
Ms. Mary Kay Turner
Senior Vice President of Patient Advocacy & Government Affairs
Dr. Ibrahim Dagher M.D. (Age 55)
Executive VP & Chief Development Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BCLI Stock Analysis - Frequently Asked Questions

Should I buy or sell Brainstorm Cell Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BCLI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCLI, but not buy additional shares or sell existing shares.
View BCLI analyst ratings or view top-rated stocks.
How have BCLI shares performed in 2024?: Brainstorm Cell Therapeutics' stock was trading at $0.2730 at the beginning of the year. Since then, BCLI stock has increased by 90.1% and is now trading at $0.5190.
View the best growth stocks for 2024 here.
Are investors shorting Brainstorm Cell Therapeutics?: Brainstorm Cell Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,340,000 shares, an increase of 57.6% from the March 15th total of 850,300 shares. Based on an average daily volume of 1,040,000 shares, the days-to-cover ratio is presently 1.3 days.
View Brainstorm Cell Therapeutics' Short Interest.
When is Brainstorm Cell Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our BCLI earnings forecast.

How were Brainstorm Cell Therapeutics' earnings last quarter?: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) announced its quarterly earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.14) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.14). During the same period in the prior year, the company earned ($0.19) earnings per share.
What other stocks do shareholders of Brainstorm Cell Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Mellanox Technologies (MLNX), Caladrius Biosciences (CLBS), Abeona Therapeutics (ABEO) and Adaptimmune Therapeutics (ADAP).
Who are Brainstorm Cell Therapeutics' major shareholders?: Brainstorm Cell Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Kingswood Wealth Advisors LLC (0.12%).
View institutional ownership trends.
How do I buy shares of Brainstorm Cell Therapeutics?: Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCLI) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis

Brainstorm Cell Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™